Medivation Hopes Details On Talazoparib Will Inspire Heightened M&A Bidding
This article was originally published in The Pink Sheet Daily
Executive Summary
Now in confidential talks with Sanofi and other buyout suitors, Medivation hopes to increase offers on the basis of its PARP inhibitor's dual-mechanism promise.